SGLT-2抑制剂、GLP-1受体激动剂与DPP-4抑制剂对CKD合并2型糖尿病患者高钾血症风险的影响:基于人群的队列研究
该研究基于美国Medicare和两个商业保险数据库(2013年4月至2022年4月),纳入CKD 3-4期合并2型糖尿病患者,比较新使用SGLT-2i、GLP-1RA与DPP-4i的高钾血症风险。经过倾向评分匹配调整140余个混杂因素后,SGLT-2i和GLP-1RA相比DPP-4i均与较低的高钾血症风险相关,支持在这类患者中使用这些药物。
要点
- 与DPP-4i相比,SGLT-2i降低高钾血症风险(HR 0.74),GLP-1RA also降低风险(HR 0.80)。
- SGLT-2i相比GLP-1RA高钾血症风险更低(HR 0.92)。
- 绝对率差显示SGLT-2i vs DPP-4i为-24.8/1000人年,GLP-1RA vs DPP-4i为-17.7/1000人年。
核心结论
- 在CKD 3-4期合并2型糖尿病患者中,SGLT-2i和GLP-1RA相比DPP-4i与较低的高钾血症风险相关。
研究设计与样本
- 基于人群的活性对照、新使用者队列研究,使用Medicare和两个美国大型商业保险数据库(2013年4月至2022年4月)的索赔数据。
- 纳入CKD 3-4期合并2型糖尿病患者,比较SGLT-2i vs DPP-4i(141671例)、GLP-1RA vs DPP-4i(159545例)和SGLT-2i vs GLP-1RA(93033例)。
- 采用倾向评分匹配调整140余个潜在混杂因素,估计合并风险比和率差。
主要发现
- SGLT-2i vs DPP-4i的高钾血症风险比为0.74(95%CI 0.68-0.80),绝对率差为-24.8/1000人年(95%CI -31.8至-17.7)。
- GLP-1RA vs DPP-4i的高钾血症风险比为0.80(95%CI 0.75-0.86),绝对率差为-17.7/1000人年(95%CI -23.4至-12.1)。
- SGLT-2i vs GLP-1RA的高钾血症风险比为0.92(95%CI 0.86-0.99),绝对率差为-5.0/1000人年(95%CI -10.9至0.8)。
- 次要结局、亚组分析及SGLT-2i和GLP-1RA类别内单药比较结果相似。
临床怎么用
- 对于CKD 3-4期合并2型糖尿病患者,优先选择SGLT-2i或GLP-1RA可能有助于降低高钾血症风险,从而支持指南推荐疗法的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperkalemia is a common adverse event in patients with chronic kidney disease (CKD) and type 2 diabetes and limits the use of guideline-recommended therapies such as renin-angiotensin system inhibitors. Here, we evaluated the comparative effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) on the risk of hyperkalemia. We conducted a population-based active-comparator, new-user cohort study using claims data from Medicare and two large United States commercial insurance databases (April 2013-April 2022). People with CKD stages 3-4 and type 2 diabetes who newly initiated SGLT-2i vs. DPP-4i (141671 patients), GLP-1RA vs. DPP-4i (159545 patients) and SGLT-2i vs. GLP-1RA (93033 patients) were included. The primary outcome was hyperkalemia diagnosed in inpatient or outpatient settings. Secondary outcomes included hyperkalemia diagnosed in inpatient or emergency department setting, and serum potassium levels of 5.5 mmol/L or more. Pooled hazard ratios and rate differences were estimated after propensity score matching to adjust for over 140 potential confounders. Initiation of SGLT-2i was associated with a lower risk of hyperkalemia compared with DPP-4i (hazard ratio 0.74; 95% confidence interval 0.68-0.80) and contrasted to GLP-1RA (0.92; 0.86-0.99). Compared with DPP-4i, GLP-1RA were also associated with a lower risk of hyperkalemia (0.80; 0.75-0.86). Corresponding absolute rate differences/1000 person-years were -24.8 (95% confidence interval -31.8 to -17.7), -5.0 (-10.9 to 0.8), and -17.7 (-23.4 to -12.1), respectively. Similar findings were observed for the secondary outcomes, among subgroups, and across single agents within the SGLT-2i and GLP-1RA classes. Thus, SGLT-2i and GLP-1RA are associated with a lower risk of hyperkalemia than DPP-4i in patients with CKD and type 2 diabetes, further supporting the use of these drugs in this population.
引用
- Fu EL, Mastrorilli J, Bykov K, et al. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023. PMID: 38101515. doi:10.1016/j.kint.2023.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。